These findings suggest that SF3B1 mutations significantly impact the splicing and the expression of UBA7. Together, these findings suggest that SF3B1 mutations contribute to MDS pathogenesis by disrupting the balance of protein post-translational modifications through aberrant alternative splicing events, consequently affecting key cancer barrier pathways. This evidence concerns the gene SF3B1 and myelodysplastic syndrome.